Taysha Gene Therapies Inc (TSHA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Taysha Gene Therapies Inc (TSHA) has a cash flow conversion efficiency ratio of -0.104x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-40.42 Million) by net assets ($387.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see TSHA stock market capitalisation for the company's overall valuation and market capitalisation.
Taysha Gene Therapies Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Taysha Gene Therapies Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Taysha Gene Therapies Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Taysha Gene Therapies Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of Taysha Gene Therapies Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kirloskar Brothers Limited
NSE:KIRLOSBROS
|
0.048x |
|
dentalcorp Holdings Ltd
TO:DNTL
|
0.037x |
|
Shanghai Highly Group Co Ltd A
SHG:600619
|
0.019x |
|
Crompton Greaves Consumer Electricals Limited
NSE:CROMPTON
|
0.013x |
|
Kennedy-Wilson Holdings Inc
NYSE:KW
|
-0.057x |
|
China National Building Material Company Limited
F:D1Y
|
0.022x |
|
Adriatic Metals Plc
AU:ADT
|
-0.451x |
|
Jiangsu Zhangjiagang Rural Commercial Bank Co Ltd
SHE:002839
|
0.253x |
Annual Cash Flow Conversion Efficiency for Taysha Gene Therapies Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Taysha Gene Therapies Inc from 2019 to 2025. View Taysha Gene Therapies Inc (TSHA) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $246.94 Million | $-93.09 Million | -0.377x | +66.80% |
| 2024-12-31 | $71.53 Million | $-81.22 Million | -1.136x | -16.55% |
| 2023-12-31 | $74.94 Million | $-73.02 Million | -0.974x | +98.95% |
| 2022-12-31 | $949.00K | $-88.39 Million | -93.140x | -7490.43% |
| 2021-12-31 | $95.38 Million | $-117.04 Million | -1.227x | -903.50% |
| 2020-12-31 | $251.30 Million | $-30.73 Million | -0.122x | +87.77% |
| 2019-12-31 | $-135.00K | $135.00K | -1.000x | -- |
About Taysha Gene Therapies Inc
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 … Read more